Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Alemany

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Journal of the National Cancer Institute|May 8, 2003
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathwayJuan Fueyo, Ramon Alemany, Candelaria Gomez-Manzano, et al.
Cancer Research|October 18, 2002
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapyMartine L M Lamfers, Jacques Grill, Clemens M F Dirven, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2021
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11Ana Mato-Berciano, Sara Morgado, María V Maliandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyMaria Jove, Irene Braña, Marc Oliva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group TrialXavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero, et al.
Journal for Immunotherapy of Cancer|February 12, 2022
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effectsMiriam Bazan-Peregrino, Rocio Garcia-Carbonero, Berta Laquente, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsRocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Journal of the National Cancer Institute|May 8, 2003
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathwayJuan Fueyo, Ramon Alemany, Candelaria Gomez-Manzano, et al.
Cancer Research|October 18, 2002
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapyMartine L M Lamfers, Jacques Grill, Clemens M F Dirven, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2021
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11Ana Mato-Berciano, Sara Morgado, María V Maliandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyMaria Jove, Irene Braña, Marc Oliva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group TrialXavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero, et al.
Journal for Immunotherapy of Cancer|February 12, 2022
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effectsMiriam Bazan-Peregrino, Rocio Garcia-Carbonero, Berta Laquente, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsRocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, et al.
Pageof 10